Skip to content
value.today
XWELL, Inc. logo

XWELL, Inc.

XWEL
$6 Mmarket cap on Oct 30, 2026-15.3% since Jan 2024
Compare
World rank
#26,753
Revenue
$29 M
For year ending December-2025
Net income
$-17 M
-58.2% margin
SEC filing
Employees
—

XWELL, Inc. in brief

XWELL, Inc. is a listed company in the Healthcare sector, based in New York, New York, USA. It was founded in 2006. Its market value was $6 M on 30 October 2026, which makes it the 26,753rd largest listed company in the world and the 4,383rd largest in the USA on this site. In the year to December 2025 it had sales of $29 M and a net loss of $17 M. Ezra Ernst is its chief executive. Its largest business segments by sales in 2025 were XpresSpa (64%), XpresTest (28%) and Naples Wax (8%). By market, the largest shares of its 2025 sales came from USA (80%). Its shares trade under the symbol XWEL (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About XWELL, Inc.

Vringo was a technology company that became involved in the worldwide patent wars. The company won a 2012 intellectual property lawsuit against Google, in which a U.S. District Court ordered Google to pay 1.36 percent of U.S. AdWords sales. Analysts estimated Vringo's judgment against Google to be worth over $1 billion. The Court of Appeals for the Federal Circuit overturned the District Court's ruling on appeal in August 2014 in a split 2-1 decision, which Intellectual Asset Magazine called "the most troubling case of 2014." Vringo appealed to the United States Supreme Court. Vringo also pursued worldwide litigation against ZTE Corporation in twelve countries, including the United Kingdom, Germany, Australia, Malaysia, India, Spain, Netherlands (the Hague), Romania, China, Malaysia, Brazil and the United States. The high profile nature of the intellectual property suits filed by the firm against large corporations known for anti-patent tendencies has led some commentators to refer to the firm as a patent vulture or patent troll.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

XWELL, Inc. timeline

6 events, 2006–2022
  1. 2006
  2. 🏁
    · approximate
    Founded
  3. 2007
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2016
  6. ✎
    Renamed FORM Holdings Corp.
    Formerly Vringo Inc.
  7. 2017
  8. ✎
    Renamed XpresSpa Group, Inc.
    Formerly FORM Holdings Corp..
  9. 2021
  10. 💰
    Record revenue of $74 million
    FY2021, the highest of the 8 years on record.
  11. 2022
  12. ✎
    Renamed XWELL, Inc.
    Formerly XpresSpa Group, Inc..

Events of XWELL, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$8 M$17 M$25 M$33 M2023202420252026

World rank over time

▲ up 779 places since 2022
2022-12-25: #27540#27,54020222023-07-30: #28460#28,46020232024-01-05: #31801#31,80120242026-03-08: #12893#12,89320262026-08-01: #23191#23,19120262026-10-14: #26553#26,55320262026-10-30: #26761#26,7612026

Rank in USA: #5,066 (Dec 2022) · #5,093 (Jul 2023) · #4,582 (Jan 2024) · #2,400 (Mar 2026) · #4,073 (Aug 2026) · #4,311 (Oct 2026) · #4,385 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.2×
Price / book
—
Free cash flow yield
-196.8%
Net margin (TTM)
-82.9%
Operating margin
-53.6%
Return on equity
—
Liabilities / assets
212.1%
Net debt
$-102M
Revenue growth
-13.8%
R&D / revenue
62.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $50M, net income $-37M$50MFY18Fiscal year ending Dec 2019: revenue $49M, net income $-21M$49MFY19Fiscal year ending Dec 2020: revenue $8M, net income $-90M$8MFY20Fiscal year ending Dec 2021: revenue $74M, net income $3M$74MFY21Fiscal year ending Dec 2022: revenue $56M, net income $-33M$56MFY22Fiscal year ending Dec 2023: revenue $30M, net income $-28M$30MFY23Fiscal year ending Dec 2024: revenue $34M, net income $-17M$34MFY24Fiscal year ending Dec 2025: revenue $29M, net income $-17M$29MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$29M-13.8%$-16M$-17M-58.2%
Dec 2024$34M+12.6%$-17M$-17M-49.7%
Dec 2023$30M-46.2%$-28M$-28M-92.1%
Dec 2022$56M-24.1%$-31M$-33M-58.7%
Dec 2021$74M+779.8%$4M$3M4.5%
Dec 2020$8M-82.7%$-40M$-90M-1079.8%
Dec 2019$49M-3.1%$-16M$-21M-43.7%
Dec 2018$50M—$-35M$-37M-74.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-9M$3M$-12M$-5.08—
Dec 2024$-11M$2M$-13M$-3.66—
Dec 2023$-16M$2M$-18M$-6.64—
Dec 2022$-24M$6M$-31M$-7.01—
Dec 2021$15M$4M$10M$0.03—
Dec 2020$-25M$4M$-29M$-2.05—
Dec 2019$-0M$2M$-2M$-12.99—
Dec 2018$-7M$3M$-10M$-25.60—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$28M
Net income, trailing 12 months
$-23M
RevenueNet income
Three months to Sep 2024: revenue $8M, net income $-5M$8MSep ’24Three months to Dec 2024 (from the annual report): revenue $7M, net income $-8M$7MDec ’24Three months to Mar 2025: revenue $7M, net income $-5M$7MMar ’25Three months to Jun 2025: revenue $8M, net income $-2M$8MJun ’25Three months to Sep 2025: revenue $7M, net income $-1M$7MSep ’25Three months to Dec 2025 (from the annual report): revenue $7M, net income $-9M$7MDec ’25Three months to Mar 2026: revenue $7M, net income $-11M$7MMar ’26Three months to Jun 2026: revenue $7M, net income $-2M$7MJun ’26

Latest quarter to Jun 2026: revenue $7M (-7.2% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of XWELL, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$29 M
Operating income
$-16 M
Net income
$-17 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$11 M
Total liabilities
$24 M
Total equity
$-22 M

As of December-2025

Top 20 institutional investors in XWELL, Inc.#

As of Sep 30, 2026
20 institutions held 377,917 shares (about 4.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 4.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 20 largest institutional investors in XWELL, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Wealthspire Advisors, LLC91,844-13,258 (-12.61%)1.07%$0 MNov 13, 2026
2BlackRock, Inc.81,9900 (0.00%)0.95%$0 MNov 13, 2026
3Geode Capital Management, LLC56,0690 (0.00%)0.65%$0 MNov 6, 2026
4Vanguard Capital Management LLC51,3100 (0.00%)0.60%$0 MNov 13, 2026
5Vanguard Fiduciary Trust Co23,3800 (0.00%)0.27%$0 MNov 13, 2026
6Citadel Advisors LLC21,510-95,512 (-81.62%)0.25%$0 MNov 16, 2026
7State Street Corp16,1440 (0.00%)0.19%$0 MNov 12, 2026
8Jane Street Group, LLC14,424-16,792 (-53.79%)0.17%$0 MNov 12, 2026
9Integrated Wealth Concepts LLC10,3520 (0.00%)0.12%$0 MNov 17, 2026
10Tower Research Capital LLC (TRC)4,581-1,173 (-20.39%)0.05%$0 MNov 16, 2026
11Morgan Stanley2,951+250 (+9.26%)0.03%$0 MNov 13, 2026
12Vanguard Global Advisers, LLC2,3830 (0.00%)0.03%$0 MNov 13, 2026
13Citigroup Inc703-5,488 (-88.64%)0.01%$0 MNov 4, 2026
14UBS Group AG204New0.00%$0 MNov 10, 2026
15Activest Wealth Management500 (0.00%)0.00%$0 MOct 15, 2026
16SBI Securities Co., Ltd.150 (0.00%)0.00%$0 MOct 22, 2026
17Steward Partners Investment Advisory, LLC30 (0.00%)0.00%$0 MNov 13, 2026
18FMR LLC2New0.00%$0 MNov 10, 2026
19Royal Bank Of Canada10 (0.00%)0.00%$0 MNov 16, 2026
20Caitong International Asset Management Co., Ltd1-7 (-87.50%)0.00%$0 MOct 29, 2026

Mutual funds holding XWELL, Inc.#

4 funds hold shares worth $0 M (about 1.1% of the company). Since their previous reports 1 added shares and 0 sold.
Mutual funds holding XWELL, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.51,310$0 M0.60%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC32,342$0 M0.38%<0.01%+8.7%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC7,323$0 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC6,204$0 M0.07%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at XWELL, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
36
since
$2 K$0Apr 2024: bought $183 (1 trades), sold $0 (0 trades)Apr 24May 2024: bought $368 (1 trades), sold $0 (0 trades)MaySep 2024: bought $2 K (1 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
XWELL, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gerard ReidDirectorGrant or award+150,000——150,000Form 4
filed Gaelle Sandra WizenbergDirectorGrant or award+50,000——240,698Form 4
filed Michael LebowitzDirectorGrant or award+50,000——261,122Form 4
filed Bruce BernsteinDirectorGrant or award+500,000——839,882Form 4
filed Robert WeinsteinDirectorGrant or award+50,000——265,231Form 4
filed Ezra ErnstPresident and CEOGrant or award+100,000——201,130Form 4
filed Bruce BernsteinDirectorGrant or award+100,000——339,882Form 4
filed Robert WeinsteinDirectorGrant or award+100,000——215,231Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: XWELL, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
117,815
1.9% of shares · 2.18 days to cover
Buybacks, Q4 2022
$0M
Q4 2022
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-20 reverse split ; 1-for-3.03 reverse split ; 1-for-1 split in the period to ; 1-for-10 reverse split ; 1-for-20 reverse split

XWELL, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2022Q4 2022$0M
Q3 2022Q3 2022$11.7M
Q2 2022Q2 2022$1M
Q1 2022Q1 2022$11.1M
Q4 2021Q4 2021$7.4M

Trading halts

  • 2026-02-25 15:09 UTC, code LUDP, resumed 15:14 UTC
  • 2026-02-25 14:49 UTC, code LUDP, resumed 14:54 UTC
  • 2024-12-16 18:10 UTC, code LUDP, resumed 18:15 UTC

Fails to deliver

  • : 1,681 shares at $0.69
  • : 87 shares at $0.72
  • : 2,632 shares at $0.74
  • : 795 shares at $0.70
  • : 8,669 shares at $0.70

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

XWELL, Inc. scorecard#

Passes 3 of the 20 checks that could be worked out: strongest in profitability (1 of 4), weakest in financial health (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median0.2×Price to sales 0.2× against Healthcare's median of 3.8×.
    • ✗Free cash flow yield above 5%-196.8%Free cash flow is -196.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-13.8%Revenue down 13.8% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-19.5%-19.5% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-19.5%-19.5% a year against Healthcare's median of 8.5% (549 companies).
    • ✗Earnings per share grew in the newest year-5.08 vs -3.66Diluted EPS -5.08 in fiscal 2025 against -3.66 the year before (report's currency).
    • ✓Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$90 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-53.6%-53.6% against Healthcare's median of -7.7% (674 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-53.6%-53.6% in fiscal 2025 against -55.7% in 2022.
  • Financial health0 of 4
    • ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.46 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-391.8×Operating income -391.8 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-63.71Z-score -63.71 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year20.6%Diluted shares up 20.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from XWELL, Inc.'s statements, beside the median of Healthcare.

XWELL, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-53.7%-7.7%
Net margin-58.2%-8.1%
Revenue growth, 3 years a year-19.5%8.5%
Revenue growth-13.8%10.2%
Free cash flow margin-40.0%-1.3%

2of 8on the Piotroski tests of financial strength

  • Revenue fell 13.8% against the year before.
  • Net loss of $17 million, the 4th loss-making year in a row.
  • Free cash flow was negative: -$12 million.
  • The share count rose 20.6% in the year.

XWELL, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

XWELL, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue29343056748.449504912r
Cost of revenue222526444112383939r6.7r
Gross profit7.58.93.71232—————
Selling, general and administrative1620r1321r24161416179.7r
Total costs and expenses2326324328r48648564r30r
Operating income−16−17−28−314.1−40−16−35−15r−18r
Interest expense and finance costs0.0—————2.91.80.71.7
Net interest income0.70.40.40.40.0−1.8−2.9———
Share of profit of associates0.00.0−0.1−0.6−1.01.3————
Other non-operating income (expense)−0.2−0.2−0.4r−1.1−1.2r0.9−4.1r−1.2−1.3r−1.6r
Income before tax−16−16−28−332.9−92−21−36−16−19r
Income tax0.00.00.00.10.10.0−0.1−0.30.10
Income from continuing operations———−333.3−90−21−36−17—
Income from discontinued operations———————−1.1−12−4.7
Net income including minority interests−16−16−28−332.9−92−21−37−28−24
Minority interests' share of net income0.90.4−0.30.2−0.5−1.70.70.50.50.0
Net income attributable to shareholders−17−17−28−333.3−90−21−37−29−24
Earnings per share, basic-5.08-3.66-6.64-7.01r0.03-2.05-12.99r-25.60-1.29-1.58
Earnings per share, diluted-5.08-3.66-6.64-7.01r0.03-2.05-12.99r-25.60-25.88r-1.58
Shares, weighted average (basic)5.64.64.24.7r104451.6r1.51.1r15
Shares, weighted average (diluted)5.64.64.24.7r105451.6r1.51.1r15
Balance sheet
Cash and cash equivalents2.64.68.419106902.23.46.418
Short-term investments0.07.21523——————
Receivables1.61.81.72.90.6————0.4r
Inventory0.50.50.91.21.80.70.60.81.22.5r
Other current assets1.21.20.91.11.11.31.11.6r2.11.6r
Current assets5.9152747109923.95.81630r
Property, plant and equipment1.71.82.53.76.74.28.1121616r
Right-of-use (leased) assets1.03.44.78.34.33.08.30——
Goodwill—1.41.44.0———02020r
Other intangible assets0.11.01.44.03.70.96.89.21214r
Total assets1125397012710329316583
Accounts payable2.81.61.12.35.5r2.47.14.6r3.4r5.2r
Debt due within a year———————6.50—
Current liabilities139.29.311201316171212
Long-term debt———————06.56.5
Lease liabilities (non-current)7.08.48.7127.56.95.8———
Total liabilities24181822272331171919
Retained earnings−490−473−456−428−395−399−308−287−250−221
Shareholders' equity−22−0.813409378−6.29.14160
Minority interests9.58.58.08.07.22.63.74.05.04.6
Total equity−137.7214810080−2.5134664
Total liabilities and equity1125397012710329316583
Shares outstanding6.15.34.24.2r101945.2r1.81.3r18
Cash-flow statement
Depreciation and amortization0.90.92.15.43.25.26.17.4r8.01.3r
Share-based compensation1.10.92.33.82.91.30.30.92.22.4r
Cash from operating activities−8.7−11−16−2415−25−0.1−6.6−12−8.4
Capital expenditure−3.0−1.8−1.9−6.5−4.3−4.0−2.3−3.0−4.5−0.1r
Intangible assets bought—−0.0−0.5−0.4−3.3−0.4—−0.1−0.20
Acquisitions, net of cash acquired——−1.4−4.9——————
Cash from investing activities4.35.95.7−35−5.2−4.3−2.3−1.9−5.43.5
Debt repaid———————−1.1−1.1r−2.0
Shares issued3.71.4—————06.60
Shares bought back———−24−7.8—————
Cash from financing activities1.91.40.0−276.41171.25.66.1−2.1
Exchange-rate effect on cash—————0.0−0.0−0.2−0.1−0.0
Change in cash−2.4−3.9−11−861688−1.3−3.0−12−7.0
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What XWELL, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Services(total)$26 M90%
  • Products(total)$3 M10%

Business segments

  • XpresSpa$19 M64%
  • XpresTest$8 M28%
  • Naples Wax$2 M7.9%

Countries and regions

  • 🇺🇸 USA$23 M80%
  • All other countries(total)$6 M20%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at XWELL, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 3 · Auditor changed 1 · Directors and officers 3 · Material agreement 5 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 3 · Bylaws or fiscal year changed 5 · Shareholder vote 4 · Results announced 5

XWELL, Inc.: events reported to the SEC
FiledWhat happenedFiling
Shareholder vote8-K
Delisting notice8-K
Material agreement8-K
Directors and officers8-K
Material agreement8-K
Shareholder vote8-K/A
Results announced8-K
Material agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Directors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed8-K
Shareholder vote8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Material agreementNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Delisting notice8-K
Auditor changed8-K
Results announced8-K
Directors and officersShareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 29, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of XWELL, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2026$31 MPrivate placement after listing$10 to $50 million1equity, optionsSEC
Jan 2025$4 MPrivate placement after listing$2 to $10 million2equity, optionsSEC
Jul 2019$3 MPrivate placement after listing$2 to $10 million1equity, debt, optionsSEC
Nov 2018$2 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
May 2018$4 MPrivate placement after listing$2 to $10 million7equity, debt, optionsSEC
Aug 2016$2 MPrivate placement after listingUnder $2 million1equitySEC
Jul 2011$3 MNo. 2$2 to $10 million11equity, debt, optionsSEC
Dec 2009$3 MNo. 1$2 to $10 million35debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Government contracts: XWELL, Inc.#

$18.8 M in federal contracts in fiscal 2026, mostly from Department of Health and Human Services.

Contracts, FY2026
$18.8 M
#252 among companies on value.today
Grants, FY2026
—
FY2027 to date
$16.7 M
contracts and grants
Since FY2008
$35.5 M
contracts and grants
  • Department of Health and Human Services$18.8 M
XWELL, Inc.: federal obligations by fiscal year
Fiscal yearContractsGrants
FY2027 (to date)$16.7 M—
FY2026$18.8 M—

Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under XWELL, Inc.: XWELL INC. (UEI LKLWP21HTK27)

How XWELL, Inc. compares in Healthcare

  • Market cap$6 M · higher than 5% of 2,013
  • Revenue$29 M · higher than 28% of 1,795
  • Net margin-82.9% · higher than 18% of 1,485
  • Revenue growth-13.8% · higher than 20% of 1,003
  • Price / sales0.2× · lower than 98% of 1,071
  • FCF yield-196.8% · higher than 0% of 835
CompanyMarket capP/ENet marginRev. growth
XWELL, Inc.🇺🇸$6 M—-82.9%-13.8%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, Wikidata, value.today research, Wikipedia, Wikimedia Commons, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at XWELL, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show XWELL, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about XWELL, Inc.? Suggest a correction